MedTrace Logo

Investigation of the Accuracy of an Automated Refractor to Provide Well-tolerated Eyeglass Prescriptions

NCT06883032 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-08-01

No results posted yet for this study

Summary

At the New England College of Optometry in Boston, MA, subjects ages 18-65 who have received or are receiving treatment for refractive error who choose to enroll in the study will be evaluated using subjective refraction and automated refraction, by way of the QuickSee Plus refractor. Subjects will then be randomized into one of two treatment plans: receive glasses from automated refraction first then subjective refraction second, and vice versa. After one week of wearing the first pair of glasses, patient preferences are assessed, and glasses are switched. After a week of wearing the second pair of glasses from the alternate measurement method, patient preferences are again assessed. Patients may then decide which pair patient like best. This is a triple blind, case-crossover clinical trial.

Conditions

  • Refractive Errors

Interventions

OTHER

AR Eyeglasses first, SR Eyeglasses second

First Eyeglasses based on Automated Refraction, Second Eyeglasses based on Subjective Refraction

OTHER

SR Eyeglasses first, AR Eyeglasses second

First Eyeglasses based on Subjective Refraction, Second Eyeglasses based on Automated Refraction

Sponsors & Collaborators

  • New England College of Optometry

    collaborator OTHER

  • National Eye Institute (NEI)

    collaborator NIH

  • PlenOptika, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-16
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06883032 on ClinicalTrials.gov